- Not yet recruitingPHASE3
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
This study looks at two existing drugs, anakinra and tocilizumab, to treat a rare, severe seizure condition called NORSE. It aims to find out which drug works better and when it should be given, as NORSE doesn't respond to usual treatments.
For: New Onset Refractory Status Epilepticus · New-Onset Refractory Status Epilepticus · Febrile Infection-Related Epilepsy Syndrome (FIRES)United States · Canada · France - AuthorisedTherapeutic exploratory (Phase II)
THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation
This study is investigating a new treatment called anakinra for seriously ill children with cancer who have dangerous inflammation and infection. It aims to see if anakinra, given early, can help more children survive compared to standard care, by calming the body's overreaction.
For: Hyperinflammation, SepsisNetherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
This study is testing a new medicine called GEN3017 for people with Hodgkin or non-Hodgkin lymphoma. It's an early-stage trial looking at safe doses and checking for side effects, as well as seeing how well the treatment shrinks the cancer.
For: Hodgkin lymphoma or non-Hodgkin lymphomaGermany · Denmark · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
This study looks at new ways to treat serious, ongoing inflammatory diseases that haven't responded to other treatments. Researchers are testing different existing medicines to see which ones work best to reduce inflammation and improve symptoms in patients with complex conditions.
For: Patients displaying a non-classified · severe and resistant inflammatory diseaseFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of care for the treatment of virus-negative myocarditis.
This study looks at a new treatment called anakinra for a heart condition called myocarditis. It aims to see if anakinra, given alongside usual care, can help improve heart function in adults whose myocarditis isn't caused by a virus.
For: endomyocardial biopsy (EBM)-proven virus-negative myocarditisItaly - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
For: Community-acquired Pneumonia, Influenza, COVID-19United States · Australia · Belgium - AuthorisedTherapeutic exploratory (Phase II)
PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
This study is looking for better ways to treat sepsis in adults. It's testing several existing medicines to see if any work well for different types of sepsis. The main goals are to improve survival and help patients recover without needing machines to support their bodies.
For: SepsisFrance - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
For: PneumoniaBelgium · Estonia · France